[{"from": "human", "value": "What can you tell me about this molecule? [C][S][=Branch1][C][=O][=Branch1][C][=O][C][=C][C@@H1][Branch2][Ring2][Branch1][C@@H1][Branch2][Ring1][S][C@@H1][Branch2][Ring1][O][C][Ring1][Branch1][=C][Branch1][Branch1][C][=C][Ring1][=Branch2][O][C][=C][C][=Branch1][#Branch2][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][#N][F][F][F][O]"}, {"from": "gpt", "value": "The molecule is an inhibitor of hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2\u03b1 protein was first identified in the 1990s by researchers at UT Southwestern Medical Center as a key player in the growth of certain cancers. Initially considered to be undruggable, a binding pocket was eventually discovered in the HIF-2\u03b1 molecule which allowed for compounds to bind and inhibit these proteins. This discovery led to the initial development of belzutifan (at the time called PT2977), which was further developed by a spin-off company named Peloton Pharmaceuticals (which itself was eventually acquired by Merck in 2019).  Belzutifan inhibits the complexation of HIF-2\u03b1 with another transcription factor, HIF-1\u03b2, a necessary step in its activation - by preventing the formation of this complex, belzutifan can slow or stop the growth of VHL-associated tumors. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021."}]